At the American Heart Association’s Scientific Sessions 2025 in New Orleans, results were discussed from a study demonstrating the potential use of a prokaryotic voltage-gated sodium channel (BacNa v) ...
Biopharmaceutical company Medera Inc. said it completed patient enrollment for Cohort B of its clinical trial evaluating SRD-002 gene therapy for heart failure with preserved ejection fraction (HFpEF) ...
BOSTON, Nov. 09, 2025 (GLOBE NEWSWIRE) -- Medera Inc. ("Medera"), a clinical-stage biopharmaceutical company focused on targeting cardiovascular diseases by developing next-generation therapeutics, ...
Medley Therapeutics (formerly YAP Therapeutics) has dosed the first cohort (n=3) with YAP101 in the Phase 1 SALVADOR-HF trial at The Texas Heart Institute at Baylor College of Medicine in the Baylor ...
First-in-human trial of AB-1002 designed to evaluate safety and preliminary efficacy in participants with New York Heart Association (NYHA) Class III heart failure Trial enrolled 11 participants in ...
A team at the Centro Nacional de Investigaciones Cardiovasculares (CNIC) has developed an innovative gene-therapy strategy that could transform the treatment of arrhythmogenic right ventricular ...
It’s now possible to treat inherited blood diseases, such as sickle cell disease, with gene editing. Blood stem cells are extracted from the patient, modified, and infused back into their bone ...
New one-dose treatment edits a gene in the liver, disabling the ANGPTL3 protein and significantly lowers cholesterol.
Results that may be inaccessible to you are currently showing.
Hide inaccessible results